Neolys Pharma has secured funding from the Mitacs Elevation programme to support new work on aminosteroid derivatives.

Elevation funds postdoctoral research fellowships carried out in partnership between a company and an academic institution. The funding allows Neolys Pharma to continue characterizing its family of compounds, including RM-581, its most advanced candidate.

The partnership continues work started in an academic setting on aminosteroid derivatives. It strengthens the link between fundamental research and the development of the company’s portfolio.